The American College of Physicians issues new guidance on the prevention of episodic migraine with pharmacologic treatment recommendations.

ACP released new clinical guidance on outpatient treatment of acute episodic migraine with combination therapy in patients ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Drinks that help relieve headaches (and sometimes migraine) do exist and are particularly helpful for when you want or need ...

There are various types of medications used to prevent migraine attacks in people living with migraine. These range from general medications like antidepressants and anti-seizure drugs that have been ...

Principal Financial Group Inc. raised its holdings in Biohaven Ltd. (NYSE ... that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product ...

HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.

Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The US-based biotech shared the ...

has settled a lawsuit against a Pfizer subsidiary for illegal kickbacks to physicians for prescribing migraine drugs. Biohaven is the pharmaceutical company that was being sued for allegedly holding ...

Bio­haven’s potas­si­um chan­nel drug has failed a late-stage study in bipo­lar ma­nia, ac­cord­ing to a state­ment in the com­pa­ny’s fourth-quar­ter earn­ings re­port.

Image credit: Shutterstock / ma_Design. Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint in a pivotal Phase II/III bipolar trial, sinking the company’s stock price. The ...